(IQV) IQVIA Holdings - Ratings and Ratios

IQVIA Holdings Inc. (NYSE:IQV) is a global leader in healthcare intelligence, clinical research, and commercial insights, serving the life sciences and healthcare industries across the Americas, Europe, Africa, and the Asia-Pacific. The company operates through three core business segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. Its Technology & Analytics Solutions segment delivers cloud-based applications, real-world evidence solutions, and consulting services to optimize commercial processes and improve patient outcomes. This segment also provides detailed performance metrics on pharmaceutical sales, prescribing trends, and promotional activities across various channels, offering insights at regional, zip code, and individual prescriber levels. The Research & Development Solutions segment focuses on clinical trial management, patient-centric solutions, and laboratory services, including genomics, bioanalytics, and vaccine development. The Contract Sales & Medical Solutions segment provides healthcare provider and patient engagement services, along with scientific strategy and medical affairs support. IQVIA serves a diverse range of clients, including pharmaceutical, biotechnology, device, and consumer health companies. Formerly known as Quintiles IMS Holdings, Inc., the company rebranded as IQVIA Holdings Inc. in November 2017 and is headquartered in Durham, North Carolina.

From a technical standpoint, IQVs recent price of $141.22 reflects a decline below its 20-day simple moving average (SMA) of $161.28, while its 50-day SMA stands at $178.83 and its 200-day SMA at $209.86. This indicates a bearish trend in the short to medium term, with a moderate average true range (ATR) of 7.15 suggesting manageable volatility. On the fundamental side, IQVIAs market capitalization of $26,297.38 million underscores its position as a major player in the life sciences tools and services industry. Its trailing P/E ratio of 19.91, compared to a forward P/E of 12.67, suggests expectations of improved earnings in the coming year. The companys return on equity (RoE) of 22.63% highlights strong profitability relative to shareholder equity.

Looking ahead, IQVIAs stock is projected to remain under pressure in the near term due to its position below key moving averages. However, its strong fundamental health, supported by a P/B ratio of 4.39 and a P/S ratio of 1.71, suggests long-term undervaluation potential. Over the next three months, the stock could test support near the $130 level, with potential upside to $160 if it regains momentum. Investors should monitor earnings reports and industry trends for cues on future performance.